September 9, 2025
City Therapeutics, founded on Kotaro Nakanishi’s Ohio State research, secures $1 billion collaboration with Biogen
Biogen is investing up to $1 billion in a new research collaboration with City Therapeutics, a biotechnology company founded on discoveries made at The Ohio State University. The agreement includes $46 million in upfront and equity funding and could deliver hundreds of millions more in milestone payments as the company advances next-generation RNA interference (RNAi) therapies.